Another potential application of IL-2 therapy that has emerged recently is employing IL-2 as a neoadjuvant to treat malignant melanoma in combination with immune checkpoint inhibitor therapies such as anti-CTLA4 and anti-PD1. Here, PDCD1 is linked to melanoma.